Market Place
Sourcing Support
Genetix Unveils 2025 Commercial Results, 2026 Strategic Plan
02 Mar 2026 //
PHARMIWEB
Minaris And Genetix Bio Expand Partnership For LYFGENIA
12 Jan 2026 //
PR NEWSWIRE
Bluebird Rebrands Post Private Buyout, as Gene Therapy Biotech
19 Sep 2025 //
BIOSPACE
Bluebird Bio Rebrands as Genetix Bio, Returns to Roots
18 Sep 2025 //
PHARMAWEB
bluebird bio Strengthens Leadership Team With New Appointments
01 Jul 2025 //
BUSINESSWIRE
Bluebird Bio Completes Acquisition by Carlyle and SK Capital
02 Jun 2025 //
BUSINESSWIRE
Carlyle and SK Capital Get Approvals to Acquire bluebird bio
05 May 2025 //
BUSINESSWIRE
Bluebird Joins CMMI Cell & Gene Therapy Access Model
04 Dec 2024 //
BUSINESSWIRE
FDA considers `regulatory action` for bluebird`s Skysona
03 Dec 2024 //
FIERCE PHARMA
FDA probes blood cancer risk from bluebird`s gene therapy
29 Nov 2024 //
REUTERS
bluebird bio Reports Inducement Grants Under Nasdaq Rule
04 Oct 2024 //
BUSINESSWIRE
Bluebird Restructures to Optimize Cost Structure and Cash Runway
24 Sep 2024 //
CONTRACTPHARMA
Vertex-CRISPR & Bluebird Begin Sickle Cell Gene Therapies
18 Sep 2024 //
BIOSPACE
Bluebird Hit With Slow Uptake of Sickle Cell, Beta-Thalassemia Gene Therapies
16 Aug 2024 //
BIOSPACE
Bluebird bio starts 15 patients on its three multimillion-dollar gene therapies
09 May 2024 //
ENDPTS
With 64 centers activated, bluebird is ready to grow Lyfgenia
09 May 2024 //
FIERCE PHARMA
bluebird First Cell Collection For LYFGENIA Gene Therapy
06 May 2024 //
BUSINESSWIRE
Vertex touts Casgevy sickle cell launch as bluebird makes progress Lyfgenia
06 May 2024 //
ENDPTS
Michigan Medicaid signs deal with bluebird for SCD gene therapy
11 Mar 2024 //
FIERCE PHARMA
Bluebird is looking for financing as it brings sickle cell therapy to market
10 Jan 2024 //
ENDPTS
Bluebird snags more outcomes-based coverage for $3M+ sickle cell gene therapy
04 Jan 2024 //
ENDPTS
Bluebird quickly raises funds to support gene therapy launches
19 Dec 2023 //
FIERCE PHARMA
Bluebird signs pact with insurer for sickle cell gene therapy
15 Dec 2023 //
REUTERS
Data Presented Support beti-cel as Curative Gene Therapy for ?-Thalassemia
10 Dec 2023 //
BUSINESSWIRE
FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease
09 Dec 2023 //
PR NEWSWIRE
Bluebird plunges after pricing sickle cell gene therapy well above competitor
08 Dec 2023 //
ENDPTS
bluebird bio to Present New and Updated Data from Gene Therapy Programs
02 Nov 2023 //
BUSINESSWIRE
Bluebird inks deal to sell lovo-cel FDA voucher for $103M
30 Oct 2023 //
FIERCE PHARMA
Bluebird’s Lovo-Cel Gene Therapy for SCD Will Not Face FDA Adcomm
17 Aug 2023 //
BIOSPACE
Bluebird touts gene therapy launches as cash remains tight
08 Aug 2023 //
FIERCE PHARMA
U.S. watchdog lifts price estimate for Bluebird, Vertex gene therapies to $2.1 million
13 Jul 2023 //
REUTERS
Bluebird gets PDUFA date for lovo-cel; FDA lifts hold on DiaMedica stroke trial
21 Jun 2023 //
ENDPTS
Bluebird`s lovo-cel application finally lands at the FDA`s desk
24 Apr 2023 //
FIERCE PHARMA
bluebird bio Submits BLA to FDA for lovo-cel for Patients with SCD
24 Apr 2023 //
BUSINESSWIRE
Vertex, bluebird SCD gene therapies can cost $1.9M
13 Apr 2023 //
FIERCE PHARMA
Bluebird Bio Expects Delay on FDA Sickle Cell Drug Application
30 Mar 2023 //
BIOPHARMADIVE
Bluebird extends cash runway to late 2024 with $113M raise
19 Jan 2023 //
FIERCE PHARMA
Bluebird touts launch progress, extends cash runway to 2024
09 Jan 2023 //
FIERCE PHARMA
